Green Lifescience Co., Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals and pesticides; and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, a piperacillin antibiotic intermediate; N,N-disuccinimidyl carbonate used for the synthesis of HIV treatment; Amoxapine, an antidepressant raw drug, and AM19, an antibiotic intermediate, as well as 1,1'-carbonyldiimidazole, which are coupling reagents used in pharmaceuticals. The company was formerly known as KPX Lifescience.Co.,Ltd. and changed its name to Green Lifescience Co., Ltd. in June 2022. The company was founded in 2005 and is headquartered in Yeosu, South Korea. Green Lifescience Co., Ltd. is a subsidiary of KPX Holdings Co., Ltd.
Metrics to compare | 114450 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship114450PeersSector | |
---|---|---|---|---|
P/E Ratio | −2.6x | −2.2x | −0.7x | |
PEG Ratio | 0.01 | 0.00 | 0.00 | |
Price/Book | 0.9x | 1.3x | 2.6x | |
Price / LTM Sales | 1.5x | 3.0x | 3.2x | |
Upside (Analyst Target) | - | 50.2% | 46.4% | |
Fair Value Upside | Unlock | 9.7% | 6.9% | Unlock |